Business Context and Reporting Period
This Form 8-K Current Report was filed by Pulse Biosciences, Inc. on December 2, 2024. The filing addresses a significant change in executive leadership and the Board of Directors. The Company is a biotechnology firm developing nano-PFA devices.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the compensation package for the departing CEO:
- Severance: 24 semi-monthly installments totaling 12 months of annual base salary.
- Bonus Replacement: A lump sum payment of $106,009.61 in lieu of the 2024 cash bonus.
- Equity Acceleration: Partial acceleration of vesting for an option award to purchase up to 101,000 shares at an exercise price of $7.45 per share.
Material Changes
The primary material change is the departure of Mr. Burke T. Barrett, who served as President and Chief Executive Officer (CEO) and a member of the Board of Directors.
- Resignation Dates: Mr. Barrett resigned from the Board effective December 2, 2024, and from his executive roles effective December 6, 2024.
- Reason for Departure: The Company states the decisions were not the result of any disagreement regarding operations, policies, or practices.
- Interim Leadership: Kevin P. Danahy (Chief Commercial Officer) and Darrin R. Uecker (Chief Technology Officer) will serve as the Company's principal executive and principal financial officers until a permanent CEO is identified. Both have previously served as CEO.
Outlook, Risks, and Management Commentary
Operational Status: Management confirms that development, clinical, and pilot commercial initiatives for the Company's three nano-PFA devices are progressing on track with previously communicated plans.
Contingencies: The Separation Agreement is contingent upon Mr. Barrett signing a release of claims. The full agreement will be filed as an exhibit to the Annual Report on Form 10-K for the year ending December 31, 2024.
Risks: The filing highlights the risk associated with the transition of leadership and the need to identify a permanent CEO replacement.
Investor Verification Checklist
- Verify the timeline for the search and appointment of a permanent CEO.
- Review the full Separation Agreement (to be filed in the 2024 Form 10-K) for additional terms or conditions not summarized here.
- Monitor upcoming communications to ensure clinical and commercial milestones remain on track during the leadership transition.
- Confirm the impact of the $106,009.61 bonus payment and equity acceleration on the Company's immediate cash burn and stock dilution.